Healthcare Equipment and Supplies
Company Overview of Bayer HealthCare LLC
Bayer HealthCare LLC develops, manufactures, and markets healthcare and medical products. The company offers blood glucose monitoring systems, diabetes self-care software, and lancing devices; and YAZ, a low-dose oral contraceptive. It also provides diagnostic testing for urinalysis, DCA, immunology, blood gas, and hematology; molecular and clinical chemistry testing to assess and manage health in a myriad of disease states, including cardiovascular, kidney and infectious diseases, oncology, and virology; and Bayer Migraine Formula, an over-the-counter medication designed to relieve migraine pain and accompanying symptoms, including nausea, phonophobia, and photophobia. The company offers an...
100 Bayer Boulevard
PO Box 915
Whippany, NJ 07981-0915
Founded in 2002
Key Executives for Bayer HealthCare LLC
President and General Manager of Animal Health Division
President and General Manager, Animal Health Division, North America
President of Consumer Care Division
Sr. Vice President, Global Head, Product Supply -Biotech and Site Head
Bayer HealthCare Representative U.S.A.
Compensation as of Fiscal Year 2014.
Bayer HealthCare LLC Key Developments
Bayer HealthCare LLC Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 09:30 AM
Apr 13 15
Bayer HealthCare LLC Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 09:30 AM. Venue: Kerry Hotel, Pudong, Shanghai, China. Speakers: Hans Lindner, VP, Head of Global External Innovation and Alliances, Global Drug Discovery.
U.S. Food and Drug Administration Accepts Bayer HealthCare's Biologics License Application for Investigational Treatment Option in Hemophilia A
Mar 4 15
Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for BAY 81-8973, a recombinant Factor VIII compound. Bayer is seeking FDA approval of the investigational compound, proposed trade name Kovaltry for the treatment of hemophilia A in children and adults. The BLA is based on results from the LEOPOLD (Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease) clinical trials, which evaluated BAY 81-8973 in adults and children using two- and three-times-per-week prophylaxis dosing regimens. The LEOPOLD Clinical Development Program consists of three multinational clinical trials designed to evaluate the pharmacokinetics, efficacy, and safety of BAY 81-8973 in subjects with severe hemophilia A.
Avivagen and Animal Health Division of Bayer Terminate U.S. Distribution Agreement for Oximunol Chewable Tablets
Feb 16 15
Avivagen Inc. announced the termination of its U.S. product distribution agreement with the Animal Health division of Bayer Healthcare LLC.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|